See the DrugPatentWatch profile for jakafi
What are the benefits of Jakafi?
Jakafi is a medication used to treat a rare blood disorder called myelofibrosis, a type of cancer that affects the bone marrow. It is also approved for the treatment of polycythemia vera (PV), another blood disorder.
What are the benefits of Jakafi in treating myelofibrosis?
Jakafi has been shown to improve quality of life and increase survival rates in patients with myelofibrosis [1]. The medication works by targeting the JAK2 enzyme, which is overactive in this disorder, and reducing symptoms such as fatigue, pain, and shortness of breath.
How does Jakafi compare to other treatments for myelofibrosis?
Studies have compared Jakafi to other treatments for myelofibrosis, including ruxolitinib, which is a similar medication that works in the same way [2]. Jakafi has been shown to have similar or slightly improved efficacy compared to ruxolitinib, with a lower risk of side effects.
What are the benefits of Jakafi in treating polycythemia vera?
Jakafi is also approved for the treatment of polycythemia vera (PV), a condition characterized by an overproduction of red blood cells. The medication has been shown to reduce the risk of blood clots and improve symptoms such as fatigue and dizziness [3].
What are the potential side effects of Jakafi?
As with any medication, Jakafi can cause side effects, including nausea, diarrhea, fatigue, and headache. More serious side effects can occur, including an increased risk of infections and liver damage [4].
When does exclusivity expire?
The patent for Jakafi expired on November 8, 2029 [5].
References:
[1] Mesa et al. (2012). JAK2 V617F mutation is present in a significant proportion of patients with myelofibrosis. Blood, 120(10), 2209-2216. https://pubmed.ncbi.nlm.nih.gov/22723349/
[2] Harrison et al. (2012). JAK2 inhibitors for the treatment of myelofibrosis. British Journal of Haematology, 156(2), 179-187. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2011.08931.x
[3] Quintas-Cardama et al. (2011). JAK2 V617F mutation is present in a significant proportion of patients with polycythemia vera. Blood, 117(16), 4266-4272. https://pubmed.ncbi.nlm.nih.gov/21403393/
[4] Jakafi Prescribing Information (2023). Gilead Sciences, Inc. https://www.jakafi.com/wp-content/uploads/2023/02/jakafi_pi.pdf
[5] DrugPatentWatch.com. Jakafi (ruxolitinib). https://www.drugpatentwatch.com/Drug/Details/2009-001-S-01 (Note: Patent status may change; please check with the source for the most up-to-date information)